Harmony Biosciences (HRMY) Tops Q4 EPS by 28c

Harmony Biosciences (NASDAQ: HRMY) reported Q4 EPS of $0.63, $0.28 better than the analyst estimate of $0.35. Revenue for the quarter came in at $91.2 million versus the consensus estimate of $91.33 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Air France-KLM (AF:FP) (AFLYY) PT Raised to EUR13.50 at UBS
• Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals